{"id":1790,"date":"2010-10-08T12:42:27","date_gmt":"2010-10-08T11:42:27","guid":{"rendered":"http:\/\/www.cdlpv.org\/dtl\/?p=1790"},"modified":"2010-10-08T12:42:27","modified_gmt":"2010-10-08T11:42:27","slug":"termes-nous-en-el-dogc-num-5-715","status":"publish","type":"post","link":"https:\/\/www.cdlpv.org\/dtl\/2010\/10\/08\/termes-nous-en-el-dogc-num-5-715\/","title":{"rendered":"Termes nous en el DOGC n\u00fam. 5.715"},"content":{"rendered":"<p>El Consell Supervisor del Termcat va aprovar durant el primer quadrimestre del 2010 nous termes i accepcions. Els hem recopilat a continuaci\u00f3 (<span class=\"versaleta\"><em>dogc<\/em><\/span> n\u00fam. 5.715, de 15.09.2010; <a href=\"http:\/\/www.gencat.cat\/eadop\/imatges\/5715\/10194060.pdf\" target=\"_blank\"><span class=\"versaleta\">[pdf]<\/span><\/a>):<\/p>\n<blockquote><p>\nc\u00e8rcida, cl\u00edmax, pastillatge, <em>torii<\/em> <a title=\"japon\u00e9s\">[ja]<\/a>, preq\u00fcela, seq\u00fcela, abandonament, aerof\u00f2bia, aleatoritzaci\u00f3 per grups, assaig cl\u00ednic, assaig cl\u00ednic no comparatiu, assaig de primera administraci\u00f3 en humans, atrici\u00f3 mostral (<em>sin.<\/em> desgast de la mostra), bioassaig, biodisponibilitat, bioequival\u00e8ncia, biosimilitud, bra\u00e7, cas, control, corba de rendiment diagn\u00f2stic (<em>sin. compl.<\/em> corba <span class=\"versaleta\">roc<\/span>), dada basal, disminuci\u00f3 progressiva de dosi, disseny amb assignaci\u00f3 al millor, disseny en quadrat llat\u00ed, disseny equilibrat, disseny no equilibrat, dosi m\u00e0xima tolerada (<em>sigla<\/em> <span class=\"versaleta\">dmt<\/span>), dosi m\u00ednima no tolerada, dosi terap\u00e8utica, dosi \u00fanica, dosi unit\u00e0ria (<em>sin.<\/em> monodosi), ect\u00f2pia del crista&#320;l\u00ed (sin. luxaci\u00f3 del crista&#320;l\u00ed), efecte romanent, equilibri cl\u00ednic, equival\u00e8ncia farmac\u00e8utica, equival\u00e8ncia terap\u00e8utica,est\u00e0ndard de refer\u00e8ncia, estudi cl\u00ednic, estudi d&#8217;abans i despr\u00e9s (sin. estudi pre-post), estudi d&#8217;ajust de dosi, estudi d&#8217;escalada de dosi, estudi de casos i controls, estudi de casos i controls niat, estudi de cohorts, estudi de dosi repetida, estudi de dosi \u00fanica, estudi de farmacovigil\u00e0ncia postcomercialitzaci\u00f3, estudi de recerca de dosi, estudi de seguretat, estudi multic\u00e8ntric, estudi observacional, estudi pilot, estudi pivot, estudi pont, estudi postautoritzaci\u00f3, estudi promocional, estudi unic\u00e8ntric, farmacovigil\u00e0ncia, febre <em>pappataci<\/em> [<em>pappataci<\/em>: <a title=\"itali\u00e0\">it<\/a>] (<em>sin.<\/em> febre per fleb\u00f2tom), grup de comparaci\u00f3 (<em>sin.<\/em> grup de control), grup de comparaci\u00f3 aparellat, grup de comparaci\u00f3 concurrent, grup de comparaci\u00f3 hist\u00f2ric, grup experimental, hipocalc\u00e8mia per avidesa \u00f2ssia, intervenci\u00f3, iris en altipl\u00e0, moviment especular, nombre necessari a cribrar (<em>sigla<\/em> <span class=\"versaleta\">nnc<\/span>), nombre necessari a tractar (<em>sigla<\/em> <span class=\"versaleta\">nnt<\/span>), p\u00e8rdua (<em>sin.<\/em> compl. baixa), per\u00edode de depuraci\u00f3, prof\u00e0rmac, prova de concepte, s\u00edndrome de l&#8217;iris en altipl\u00e0, tractament de comparaci\u00f3, tractament experimental, biocarb\u00f3, captura de di\u00f2xid de carboni, captura i emmagatzematge de di\u00f2xid de carboni (<em>sigla<\/em> <span class=\"versaleta\">cedc<\/span>), emmagatzematge de di\u00f2xid de carboni, fixaci\u00f3 de carboni, ritme circadiari, panel, panelista, auditoria preventiva, associaci\u00f3 de marques, reconstrucci\u00f3 de marca, canicr\u00f2s, an\u00e0lisi d&#8217;agrupaments, distribuci\u00f3 khi quadrat, distribuci\u00f3 log-normal (<em>sin.<\/em> distribuci\u00f3 logar\u00edtmica normal), khi quadrat (<em>s\u00edmbol<\/em> X\u00b2), prova khi quadrat, prova khi quadrat de Pearson, variable de confusi\u00f3, acer patentat, autoportant, c\u00e0rrega de derivaci\u00f3, patentatge, inform\u00e0tica en n\u00favol, reposador -ra, wok.\n<\/p><\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>El Consell Supervisor del Termcat va aprovar durant el primer quadrimestre del 2010 nous termes i accepcions. Els hem recopilat a continuaci\u00f3 (dogc n\u00fam. 5.715, de 15.09.2010; [pdf]): c\u00e8rcida, cl\u00edmax, pastillatge, torii [ja], preq\u00fcela, seq\u00fcela, abandonament, aerof\u00f2bia, aleatoritzaci\u00f3 per grups, assaig cl\u00ednic, assaig cl\u00ednic no comparatiu, assaig de primera administraci\u00f3 en humans, atrici\u00f3 mostral (sin. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,30],"tags":[467],"class_list":["post-1790","post","type-post","status-publish","format-standard","hentry","category-general","category-terminologia","tag-termcat"],"_links":{"self":[{"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/posts\/1790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/comments?post=1790"}],"version-history":[{"count":0,"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/posts\/1790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/media?parent=1790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/categories?post=1790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cdlpv.org\/dtl\/wp-json\/wp\/v2\/tags?post=1790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}